Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04752696
Title Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Cardiff Oncology

pancreatic ductal adenocarcinoma


Fluorouracil + Leucovorin + MM-398 + Onvansertib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.